• The company’s share price recently reached a 52-week high, a significant milestone that reflects a period of robust trading and investor optimism.
• D-Wave continues efforts to expand its board of directors with experienced tech executives to assist the company’s aggressive go-to-market strategy and accelerate adoption of its annealing quantum computing technology.
• The latest board addition, Sharon Holt, is a veteran technology executive, investor and board director with extensive global industry experience.

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, has seen a remarkable share price surge in recent weeks, reporting a 52-week high. The price increase is a significant milestone for the company, reflecting a period of robust trading and investor optimism (https://ibn.fm/QBIw4).

To support its aggressive go-to-market efforts amid accelerating adoption of its annealing quantum computing solutions, D-Wave has added several key members to its board of directors in recent weeks, including John DiLullo and Rohit Ghai in October 2024. The latest addition, announced on Nov. 25, is Sharon Holt, a veteran technology executive, investor and board director with extensive global industry experience in semiconductors, embedded technologies and intellectual property (https://ibn.fm/ysqzY).

“We’re witnessing the onset of a new era of computation, as quantum shifts from an experimental technology to an essential solution for any organization looking to solve its toughest problems,” said Holt. “As the world’s first commercial quantum computing company, D-Wave is at the forefront of this quantum transformation, and I’m looking forward to supporting the company as it helps customers harness the power of quantum for measurable impact today.”

Throughout her career, Holt has had executive roles spanning business unit leadership, P&L ownership, business development, sales, marketing and engineering. Holt held executive roles at Agilent Technologies and HP and until 2016, she served as senior vice president and general manager of the semiconductor business group at Rambus Inc., a leading technology development and licensing company. Since 2016, she has served as a principal at Fraser Stuart Ventures, LLC, a private investment and advisory firm.

Holt also serves on the board of directors of Infinera Corp., a publicly traded supplier of intelligent transport network solutions, and previously served as chair of the board of directors of Immersion Corporation, a publicly traded developer of haptics technology for cell phones and other devices.

D-Wave board chair Steve West said the board was very excited to welcome Holt as a new member to assist the company’s efforts to fuel the global adoption of annealing quantum computing. “Her proven business leadership coupled with a background in successful go-to-market strategies are well-suited for maximizing impact of the company’s growth initiatives,” West said.

D-Wave CEO Dr. Alan Baratz said Holt’s addition to the board was perfectly timed to help the company capitalize on its unique position and advantages in the process of developing a profitable and solid business. “D-Wave’s opportunity is significant, supported by remarkable product development, rapidly growing customer adoption and ongoing scientific advancements,” said Dr. Baratz.

For more information, visit the company’s website at www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

• The company anticipates a 70% increase in membership in the upcoming year, growing the current number of members from 13,000 in June 2024 to 20,000 in 2025.
• The fourfold increase in membership reflects the growing demand for a change in approach to healthcare that combines innovative personalized strategies with a deep understanding of the served communities.
• The company has established a strong network of over 12,940 providers, enabling it to offer comprehensive care to its rapidly growing member base, especially in Southern California.

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan, dedicated to reshaping personalized and comprehensive healthcare, anticipates strong growth in membership in 2025, building upon the record-setting performance already achieved this year in terms of network and membership expansion.

According to a company news release, membership is expected to grow by 70% or 7,000 members in the upcoming year, a major increase from the numbers reported this year (https://ibn.fm/VbZnF). Astiva Health started off with a membership jump in January 2024, when it reached 10,000 members (22% higher than the 3,100 members recorded in January 2023), and then again in June 2024 when 13,000 members were recorded.

This remarkable membership increase of more than four times reflects the growing demand for Astiva Health’s unique services and approach to healthcare. The company’s core mission is to efficiently deliver innovative health plans customized to meet its members’ specialized needs, including a culturally responsive approach to healthcare via multilingual solutions for customer service, marketing materials and educational resources.

“We are thrilled to continue building on the momentum we’ve achieved this year,” said Dr. Tri T. Nguyen, Co-founder and CEO of Astiva Health. “Our growth is a testament to the value our culturally aware, personalized healthcare model brings to our members. As we project adding another 7,000 members in 2025, we are committed to expanding our services and enhancing the quality of care we provide.”

Astiva Health’s dedication to serving the underserved population, particularly in Southern California, positioned the company to tap into a market segment with significant growth potential, and allowed it to consistently exceed growth expectations. In addition to the remarkable increase in membership, the company successfully established a strong network of over 12,940 providers, including 10,355 specialists and 2,585 primary care physicians, enabling it to offer comprehensive care to its rapidly growing member base.

Astiva Health also focuses on meeting the growing demand for quality Medicare Advantage plans, offering a type of plan with prescription drug coverage, so members have no need for a separate Part D plan. The company provides a range of options that prioritize member satisfaction and comprehensive care, with the goal of addressing the unique needs of seniors, providing access to extensive networks of healthcare providers and specialized services.

“Astiva Health’s commitment to excellence in healthcare has positioned us for this incredible growth trajectory,” said Chi Luong, CFO of Astiva Health. “As we look forward to 2025, we remain focused on delivering innovative healthcare solutions that cater to the unique needs of our diverse communities. We are excited about the opportunities ahead and remain dedicated to providing our members with the highest level of care.”

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva are available in the company’s newsroom at https://ibn.fm/Astiva

• In just over one year, Torr Metals has identified six undrilled gold anomalies covering a 1.2 x 2-kilometer (“km”) corridor, with gold soil grades up to 1.32 g/t Au along the Trans-Canada Highway; additional 2024 surface assays pending testing a highly prospective 7 km strike-length to potential mineralization
• At the 100% owned Kolos Copper-Gold Project, Torr’s inaugural soil sampling over the past year defined a 7 km porphyry trend with three undrilled copper-gold centers, boasting a footprint 33% larger than Copper Mountain Mine and double the average grades of regional deposits
• Investors can look forward to continued updates on upcoming surface sample assays, ground geophysical surveys, and the launch of inaugural drill programs at both the Kolos and Filion projects. These initiatives aim to explore newly identified high-grade copper-gold porphyry systems at Kolos and test undrilled gold soil anomalies at Filion, potentially unlocking district-scale discoveries within two of Canada’s most prolific mineral belts

Torr Metals (TSX.V: TMET) is an emerging player in Canada’s mining sector, presenting a compelling case for exploration-focused investors. Here are four key points to know about Torr and its compelling projects:

1. District-Scale Opportunities in Prime Locations

Torr Metals prioritizes highway-accessible, early-stage district-scale projects to enhance exploration efficiency and minimize costs. By operating in regions where major mining companies have established operations with near-term feed requirements, Torr positions itself as a standout in the mining sector, strategically aligning its exploration efforts with industry demands.

Its 100%-owned portfolio includes the Filion Gold Project (261 km²) in Ontario, the Kolos Copper-Gold Project (240 km²) in British Columbia, and the Latham Copper-Gold Project (689 km²) in British Columbia’s Golden Triangle—together spanning 1,189 km² of highly prospective mineral-endowed land packages.

Spanning 261 km² in Ontario, Filion is strategically located in northern Ontario near the Trans-Canada Highway and sits within a prolific mining region. Torr’s maiden exploration program in late 2023 revealed six undrilled gold soil anomalies, signaling significant untapped potential. Torr is currently systematically targeting these anomalies through its ongoing large-scale exploration program to test expansion potential and refine targeting for a future maiden drill program.

Kolos spans 240 km² in southern British Columbia, notably located along Canada’s Copper Highway within the prolific Quesnel Terrane. Situated near Canada’s largest open-pit copper mine, Highland Valley, and only 40 kilometers from Kamloops along Highway 5, Kolos benefits from year-round access and established mining infrastructure.

In early 2024, Torr released maiden soil sample results identifying a 7 km porphyry trend encompassing three potential undrilled copper-gold centers. Remarkably, the total footprint of these clustered centers is 33% larger than the nearby Copper Mountain Mine and features double the typical grades of mineralization. These results position Kolos as a new copper-gold exploration opportunity with immense growth potential in a long-lived copper jurisdiction.

Latham covers a sprawling, district-scale 689 km² within the famous “Golden Triangle” region of British Columbia, just 20 km south of Dease Lake with year-round access via Highway 37. Latham boasts six large-scale Cu-Au exploration targets that have never been drilled, alongside the historical Gnat Pass deposit, which features 102 drill holes from the 1960s, outlining a non-compliant resource of 33 Mt at 0.39% Cu (~284 million pounds of copper)¹. The region is host to major copper-gold porphyry operations, including Red Chris and Galore Creek, and has seen nearby high-profile acquisitions like Newmont’s US$311 million takeover of Saddle North in 2021 and Newcrest’s US$804 million purchase of a 70% stake in Red Chris in 2019.

2. Breaking New Ground Through High-Tech: Laying the Foundations for Multiple Inaugural Exploration Programs

Torr Metals has utilized cutting-edge LiDAR technology (Light Detection and Ranging) to uncover high-priority exploration zones in regions historically obscured by thin till cover. At the Filion Gold Project, LiDAR surveys identified 17 previously undocumented historical trenches and 18 new rock outcrops along known VLF-EM conductors, enabling precise surface sampling. The recently concluded 2024 program, which included extensive soil and rock sampling, focused on expanding mineralized zones first delineated in 2023, where gold anomalies spanned a 1.2 km x 2 km corridor centered on the Millar East occurrence. With historical grades as high as 91.4 g/t Au, this work is laying a strong foundation for inaugural drill programs designed to test and expand these promising targets.

At the Kolos Copper-Gold Project, the company will be looking to add to the legacy of the region, where its land is surrounded by multiple long-lived copper mines at Highland Valley (30 km to the northwest), New Afton (30 km to the north), and Copper Mountain (106 km to the south). Notably, initial 2024 fieldwork uncovered the Sonic Zone, a newly identified area of strong magmatic-hydrothermal alteration spanning 1,000 x 2,000 meters. Rock grab samples returned anomalous copper and gold values, suggesting potential for another large-scale Cu-Au porphyry system. This discovery aligns with Torr’s exploration model, complementing the established porphyry centers at Kirby, Lodi, Ace, and Rea to the south, further solidifying Kolos as a promising district-scale opportunity.

3. Charting a New Era of Discovery: Torr Metals Delivers a Series of Transformative Firsts at Filion and Kolos

Torr Metals has consistently demonstrated its ability to identify and advance high-potential exploration targets through innovation and a systematic approach. At Filion, the application of LiDAR technology and targeted surface sampling has uncovered new high-grade zones, establishing a foundation for inaugural drilling on undrilled gold soil anomalies grading up to 1.32 g/t Au in 2023. At Kolos, the discovery of the Sonic Zone represents a significant step forward, identifying another potential large-scale Cu-Au porphyry system alongside previously established targets. These efforts exemplify Torr’s knack for placing a finger on the “needle in the haystack” and transforming untapped potential into value-driven exploration opportunities. By leading with “firsts” at both Filion and Kolos, Torr is building a portfolio of high-quality targets at a low cost to investors poised for potentially significant fresh discoveries.

4. Resilience Amid Geopolitical Shifts

As global trade policies evolve – particularly with the upcoming return of Donald Trump to the U.S. presidency – Torr Metals’ focus on Canadian assets insulates it from trade protectionism risks. The company’s strategic alignment with domestic opportunities ensures it remains adaptable to shifting market dynamics, including rising gold prices and demand for critical metals.

Torr Metals is poised for substantial growth as it advances its innovative exploration strategies across high-potential projects. With ongoing fieldwork through the winter and a series of impactful news releases on the horizon, Torr is an exciting company to watch. For investors seeking exposure to underexplored and strategically positioned copper and gold exploration opportunities, Torr offers a compelling prospect heading into Q4 and the new year.

¹ Ashbury, D.W. (1972): Ore reserves – Dease Lake Mines: personal communication sent by D.W. Ashbury to Dr. S.P. Ogryzlo dated April 28, 1972, 2p.

For more information, visit the company’s website at www.TorrMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMET are available in the company’s newsroom at https://ibn.fm/TMET

• Thumzup offers a unique platform designed to democratize the multi-billion-dollar social media marketing industry.
• The company combines programmatic advertising with user-generated content to create high-impact campaigns.
• Thumzup achieved 202% growth in advertisers on its platform through October 2024, showcasing strong traction.
• Recent video integration with Instagram Reels enhances platform capabilities and expands advertiser options.
• The company operates in a rapidly growing market with strong long-term growth potential, led by an experienced leadership team.

Thumzup (NASDAQ: TZUP) is at the forefront of modernizing the social media branding and marketing industry with its unique platform designed to connect advertisers directly with everyday social media users. The company’s mission is to empower individuals by turning their authentic social media activity into a monetizable asset while providing brands with cost-effective and impactful advertising solutions.

Through its flagship Thumzup platform, the company offers a seamless system where users post about participating advertisers and receive cash payments via Venmo or PayPal. Thumzup recently announced plans to integrate bitcoin as an additional payment option, expanding accessibility for gig economy workers.

By prioritizing accessibility and transparency, Thumzup is redefining traditional marketing strategies with an inclusive, user-driven approach. It is leveraging its scalable technology to disrupt the status quo, offering a win-win ecosystem for advertisers and users alike.

The company is headquartered in Los Angeles, California.

Products

Thumzup’s key offering, the Thumzup platform, features two integrated components: a sophisticated advertiser dashboard and an intuitive consumer-facing app. The advertiser dashboard provides companies with tools to design, manage and analyze campaigns.

On the consumer side, the Thumzup app allows users to participate in campaigns by posting approved content to their social media accounts. In exchange, users receive direct cash rewards.

Recent enhancements to the platform include the launch of video capabilities, enabling integration with Instagram Reels. This update allows advertisers to tap into the growing popularity of short-form video content, broadening campaign possibilities.

The platform not only incentivizes users but also delivers authentic, relatable content for advertisers, bridging the gap between grassroots engagement and effective campaign management.

Market Opportunity

The global social media advertising market is projected to reach $219.8 billion in 2024, with an expected annual growth rate of 3.86%, resulting in a market volume of $255.8 billion by 2028, according to Statista. Thumzup targets the intersection of this growth with the rise of micro-influencers and everyday social media users, a segment that remains largely untapped in the advertising ecosystem.

In October 2024, Thumzup achieved 202% year-over-year growth in advertisers on its proprietary platform, demonstrating significant traction and scalability. With plans for further expansion in both advertiser partnerships and user engagement, the company is well-positioned to capitalize on the growing demand for authentic and trust-building marketing strategies. As Thumzup integrates innovative features like video support and continues its geographic expansion, it is poised to capture a larger share of the rapidly growing social media advertising market.

Leadership Team

Robert Steele, Founder and Chief Executive Officer of Thumzup, has over 25 years of experience as a technologist and entrepreneur. He has successfully launched multiple companies, including iBrite, a pioneer in mobile software development. Mr. Steele’s leadership and innovative vision drive Thumzup’s mission to democratize the social media marketing industry.

Robert Haag, Director of Thumzup, is the Managing Member of Westside Strategic Partners LLC and a Managing Director at IRTH Communications. With decades of experience in financial communications, investment and corporate strategy, Mr. Haag provides critical guidance on strategic initiatives and business growth.

Dr. Joanna Massey, member of the company’s Board of Advisors, brings over 25 years of executive experience with Fortune 500 companies and startups to Thumzup. She has held senior roles in communications at Lions Gate Entertainment and CBS Corporation. Dr. Massey leverages her expertise to support Thumzup’s growth strategy.

For more information, visit the company’s website at www.ThumzupMedia.com.

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

• Adageis operates in the rapidly expanding AI healthcare market, projected by Fortune Business Insights to reach $490.96 billion by 2032.
• The ProActive Care Platform offers seamless integration with existing EMR systems, reducing adoption barriers for healthcare providers.
• Partnerships with prominent organizations, such as HealthyU Clinics, and its status as an AthenaHealth marketplace partner, demonstrate Adageis’ growing influence in the healthcare sector.
• The company’s AI-driven predictive analytics enhance patient care and operational efficiency, aligning with the industry’s shift toward value-based care models.
• Led by a seasoned leadership team with extensive experience in healthcare and technology, Adageis is well-equipped to navigate the evolving healthcare landscape.

Adageis is a healthcare technology company dedicated to revolutionizing patient care through innovative solutions. By integrating artificial intelligence (“AI”) and machine learning, Adageis addresses inefficiencies in healthcare delivery, enabling providers to enhance patient outcomes and streamline operations. The company focuses on leveraging advanced technology to meet the growing demand for value-based care and quality incentives in the healthcare sector.

With a commitment to innovation and practical solutions, Adageis empowers clinics, healthcare centers, and care networks to implement its ProActive Care Platform without the need for expensive platform changes or extensive staff training. This approach reduces barriers to adoption and helps healthcare organizations maximize their potential in an increasingly complex industry landscape.

Recent collaborations, including its partnership with HealthyU Clinics and integration with AthenaHealth as a marketplace partner, underscore Adageis’s industry relevance and adaptability.

Adageis is headquartered in Mesa, Arizona.

Services

Adageis offers the ProActive Care Platform, an AI-driven solution designed to integrate seamlessly with existing Electronic Medical Records (“EMR”) systems.

This platform enables healthcare providers to deliver patient-centric care while maximizing reimbursements from quality metrics and value-based contracts. Key features include:

• Predictive Analytics: Utilizes AI to analyze patient data, identifying high-risk individuals and care gaps to improve health outcomes and reduce costs.
• Efficiency and Cost Reduction: Continuously monitors patient health, allowing providers to offer proactive care even outside traditional office visits, thereby enhancing efficiency and lowering expenses.
• Flexible Integration: Compatible with various EMR systems, including AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, facilitating easy adoption without the need for extensive staff training or platform changes.

Market Opportunity

The global AI in healthcare market is experiencing rapid growth, driven by the increasing demand for enhanced efficiency, accuracy, and better patient outcomes. In 2023, the market was valued at approximately $19.27 billion by Grand View Research, and it is projected to grow at a compound annual growth rate of 38.5% from 2024 to 2030. This growth is fueled by the increasing need for solutions that can analyze large datasets, reduce costs, and improve care delivery across the healthcare continuum.

Adageis is well-positioned to capitalize on these trends. Its ProActive Care Platform offers AI-driven predictive analytics and proactive care solutions that align with the industry’s shift toward value-based care. By providing seamless integration with existing EMR systems and focusing on operational efficiency, Adageis enables healthcare providers to meet the demands of a rapidly evolving market.

Leadership Team

Shane Speirs, MD, MBA serves as the company’s CEO. He is a board-certified physician in family and geriatric medicine with extensive experience in healthcare leadership, data modeling, and AI applications in healthcare delivery. He holds an MBA in Healthcare Management from the W.P. Carey School of Business and has a proven track record in managing telehealth and AI-focused healthcare companies.

Bill Jentarra, MBA is the CTO of Adageis, bringing over 25 years of experience in architecting and implementing complex client relationship management (“CRM”) and business intelligence (“BI”) solutions across various industries, including healthcare. His expertise encompasses the entire lifecycle of CRM and BI projects, ensuring practical and cost-effective technology applications to solve complex business problems.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

• Among the most notable technical achievements was the completion of the calibration of a 4,400 qubit Advantage2(TM) processor, capable of solving much larger and complex problems with faster time-to-solution than earlier generation processors.
• D-Wave earned “awardable” status on the U.S. Department of Defense’s Tradewinds buying platform, gaining increased visibility with U.S. government customers.
• New partnerships and collaborations include working with NTT DOCOMO, Japan Tobacco Inc., Staque and the Chicago Quantum Exchange.

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, recently announced Q3 2024 business results, highlighting several key operational milestones and technological achievements, including new partnerships and developments in driving the adoption of quantum computing technology.

“Annealing quantum computing is continuing to drive the commercial adoption of quantum technology,” said Dr. Alan Baratz, CEO of D-Wave, in a company news release (https://ibn.fm/ZjaSa). “Organizations around the world – from Vinci Energies in Europe to NTT DOCOMO in Japan – are recognizing the value our technology can bring right now in fueling new discoveries, facilitating operational excellence and driving measurable outcomes.”

One of the most notable achievements was the recently completed calibration of a 4,400 qubit Advantage2 processor, a significant technical development milestone. With nearly four times more qubits than the previous Advantage2 prototype, with 1,200 qubits, this new processor is capable of solving much larger and complex problems with faster time-to-solution, increased qubit connectivity and a 40% increase in energy scale when compared to the prior generation Advantage processor.

As part of its quantum AI product roadmap efforts, D-Wave continues to make progress on exploring generative AI architectures that directly use quantum processing unit (“QPU”) samples from quantum distributions, with the goal of supporting faster and more energy-efficient model training and inference.

D-Wave also continued implementing its go-to-market growth strategy, launching the quantum optimization market category with a collection of website content and assets that showcase key use cases such as workforce and production scheduling, vehicle routing, resource optimization, and cargo loading. To further help drive the company’s next phase of growth and the continued commercial adoption of quantum computing, D-Wave expanded its executive leadership with a new chief human resources officer, Sophie Ames, and three new board members, John DiLullo, Rohit Ghai and Sharon Holt.

Other notable business updates include:

• D-Wave earning “awardable” status on the U.S. Department of Defense’s Tradewinds buying platform, which is designed to accelerate the procurement and adoption of emerging technologies.
• D-Wave’s annealing quantum computing solutions being used by Japan’s largest mobile phone operator, NTT DOCOMO, in the production deployment of a hybrid-quantum application, for the optimization of mobile network performance.
• A new collaboration with Japan Tobacco Inc. to build a proof-of-concept that leverages quantum computing technology and AI in the drug discovery process.
• A strategic partnership with Staque, designed to accelerate the commercial adoption of annealing quantum computing in the Middle East. The partnership was announced at the first-ever Qubits UAE users’ event in Dubai, a tailored version of D-Wave’s annual Qubits user conference.
• Joining the Chicago Quantum Exchange (“CQE”) as a corporate partner, aiming to engage with the CQE community on materials science research, quantum education, and the development of practical optimization use cases.

For more information, visit the company’s website at www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

• The webcast led by Annovis’ Founder, President and CEO, Maria Maccecchini, Ph.D., will take place on Dec. 11, at 4:30 p.m. EST.
• Dr. Maccecchini will provide a comprehensive view of the company’s recent achievements along with strategic initiatives for 2025, followed by a Q&A session.
• The company recently received FDA clearance to proceed with a pivotal Phase 3 Alzheimer’s disease program for lead drug candidate buntanetap, set to begin in early 2025.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a live investor webcast on Dec. 11, 2024, at 4:30 p.m. EST, to provide key operational highlights and year-end clinical updates (https://ibn.fm/69VpQ).

The investor webcast will be led by Annovis’ CEO, Maria Maccecchini, Ph.D., who will share a comprehensive update on the company’s recent achievements, ongoing clinical programs and strategic initiatives for 2025.

Key topics addressed during the webcast will include:

• Clinical Progress: Updates on Phase 3 studies for AD and PD.
• Regulatory Milestones: Insights into interactions with the U.S. Food and Drug Administration (“FDA”) and upcoming submissions.
• Financial Overview: Summary of the company’s financial health and funding strategies.
• Strategic Outlook: Plans for advancing neurodegenerative disease therapies in the coming year.

The company recently received FDA clearance to proceed with a pivotal Phase 3 study for buntanetap in early AD, set to begin in Q1 2025. The FDA clearance came after the company presented encouraging results of a recently completed Phase 2/3 AD study which showed that buntanetap significantly improved cognition in patients with early AD by 3.3 points on the ADAS-Cog11 test after three months of treatment, compared to a 0.3-point improvement in the placebo group.

Buntanetap is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression.

A separate Phase 3 PD clinical trial indicated that buntanetap led to significant improvements in motor skills, daily functions and cognition in the per protocol PD population. The drug also halted cognitive decline in the intent-to-treat population. The company is now preparing for a meeting with the FDA to align on the next steps for its PD program, to be held in Q1 2025.

“Our priority is to bring a safe and effective treatment to patients, and we are committed to ensuring the next clinical trials are executed at the highest standards to attain an expedited NDA submission,” Dr. Maccecchini said in a recent episode of IBNs’ The BioMedWire Podcast (https://ibn.fm/E592U).

Investors and parties interested in attending the webcast on Dec. 11 can register in advance (https://ibn.fm/Qb3Es). During the event’s Q&A session, the Annovis CEO will also answer as many questions as possible, and participants are encouraged to submit their inquiries in advance via email at ir@annovisbio.com.

For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X, and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

• SuperCom’s superior electronic monitoring (“EM”) technology is highly competitive when it comes to tracking house arrest subjects and domestic violence offenders, allowing the company to expand its client base and revenue performance this year
• Israel-based SuperCom is improving law enforcement agencies’ capacity to monitor offenders on supervised release as a community-building and budget-conscious alternative to incarceration and to help reduce recidivism
• The company recently reported third-quarter financial information, including data on YoY revenue growth from $20.9 million to $21.3 million in the first 9 months and $6.78 million to $6.91 million during Q3. Also, the company reported on YoY EBITDA growth from $3.7 million to $4.6 million in the first 9 months.
• SuperCom’s recent client contract wins have included expansion into various states in North America, plus over $13.5 million in projects for European governments

Electronic monitoring (“EM”) technology developer SuperCom (NASDAQ: SPCB) reported the success of its international expansion initiatives recently in a Q3 earnings call that included details about increased revenue and gross profit margin.

SuperCom has developed EM technology under its PureSecurity platform, which offers competitive performance improvements over legacy services in domestic violence offender tracking, house arrest monitoring, and other critical GPS-based tracking applications.

The company’s production of a device with a battery life of up to one year without recharging makes it particularly attractive to clients. In addition, its sleek, unobtrusive visuals further the industry’s aim of helping offenders and accused individuals reintegrate into society and avoid reoffending rather than being incarcerated in an overcrowded and costly prison system.

SuperCom’s Nov. 14 report highlighted its ongoing increase in revenue to $21.3 million for the first nine months of the year, as well as a dramatic improvement in gross profit margin to 50.1% from 30.7% on a year-over-year basis (https://ibn.fm/zYuPj).

“Our financial results for the third quarter and the first nine months of 2024 reflect the successful execution of our strategic initiatives, which have been driving revenue growth, improving profitability and enhancing cash flow,” SuperCom President and CEO Ordan Trabelsi stated (https://ibn.fm/4j0E1). “This quarter was particularly exciting as we solidified our leadership position with key contract wins, including the prestigious National Israeli Electronic Monitoring project. We also expanded into new regions, including New York, West Virginia and Maryland, further strengthening our footprint in the U.S. market.”

The Israeli Prison Service state agency (“IPS”) project will allow authorities to monitor an estimated 1,500 enrollees nationwide in all of the country’s EM offender programs for five years (already underway), with an option to extend the contract for four additional periods of one year.

SuperCom’s use of GPS and RFID technology allows trackers to see the movements of supervised individuals in three dimensions, with elevation data incorporated into information on where someone is located on a grid plane. That ability is particularly useful when the monitored subject is in a high-rise apartment or office building.

The technology notifies authorities if boundaries are trespassed by the monitored individuals and can also notify identified potential victims via smartphone, giving them an opportunity to take preventative or defensive measures in a timely fashion.

The Q3 report also notes that the company has reversed an operating loss to finish with an operating income of $1.13 million, evidence of the company’s financial discipline.

“The U.S. market moves faster than Europe, often involving counties and resellers rather than national projects. This requires more feet on the ground due to the fragmented market,” Trabelsi said. “We are focused on maintaining profitability while optimizing our cash use and sales efforts. We have seen growth even as we work efficiently with our capital.”

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Brera Holdings, an Ireland-based, international holding company with a global portfolio of men’s and women’s sports clubs, has noted a spike in Italian Serie B club and player market values between June 15, 2024, and Nov. 12, 2024
• Key clubs such as Carrarese Calcio, SS Juve Stabia and Cesena FC posted a 151%, 146.7% and 143.4% increase in valuations, respectively, over the study period
• According to Brera’s management, this trend highlights Serie B’s growing importance both as a developmental league and as a place where young talent thrives
• It further validates the company’s commitment earlier in the year to enter the Italian Serie B football space with its exclusive letter of intent to acquire a team in the league

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach, is encouraged by recent positive valuations across Italy’s Serie B pro football league. This follows a spike in club and player market values, based upon data from Transfermarkt, which highlights the growing interest in the sport, along with the growing importance of Serie B as a developmental league where young talent is refined and prepped for success in Serie A and beyond (https://ibn.fm/Nburg).

In its study, which evaluated data between June 15, 2024, and Nov. 12, 2024, Brera noted that several teams in Serie B saw a significant uptick in valuations. Most notably, Carrarese Calcio 1908 recorded a 151% jump, from €5.25 million to €13.18 million. SS Juve Stabia also posted a 146.7% increase in valuation from €4.23 million to €10.43 million, while Cesena FC posted a 143.4% increase, climbing from €9.4 million to €22.88 million (https://ibn.fm/Nburg).

This growth in valuation extended beyond the clubs themselves to the individual players. Rachid Kouda, a standout in midfield and a key player in Spezia Calcio, had his valuation grow from €0.8 million to €3.5 million, a 338% growth. Tommaso Berti, a Cesena FC midfielder, posted a 200% growth in valuation from €1 million to €3 million. At the same time, Francesco Pio Esposito, an 18-year-old striker for Spezia Calcio, had his valuation grow from €2 million to €5 million.

Brera Holdings’ management believes that this ongoing trend highlights Serie B’s growing importance as a developmental league and a place where young talent thrives. It further validates its commitment earlier in the year, which saw it sign an exclusive letter of intent to acquire an Italian Serie B football club (https://ibn.fm/x3mHf). It is confident that, with such an investment, it will reap rewards that come with continued growth and will play an integral role in further advancing Italy’s and Europe’s football leagues. While short-term success has been shown to drive quick increases in valuations, Brera believes that long-term player development is integral. As such, it looks to lean into that approach, building talent and growing its team slowly.

“Clubs like Brescia Calcio, known for their storied youth academy, continue to produce top-tier talent, ensuring sustainable growth,” commented Brera Holdings’ CEO, Pierre Galoppi. “Their focus on youth development is proving to be a cornerstone of long-term success,” he added (https://ibn.fm/Nburg).

For additional information, visit the company’s website at www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

Zomedica (NYSE: ZOM) is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Their gold standard PulseVet(r) shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Their suite of products also includes the Assisi(r) Loop line of therapeutic devices and the TRUFORMA(r) diagnostic platform, the TRUVIEW(tm) digital cytology system, and the VetGuardian(r) no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $78 million in liquidity as of September 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as they work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information, visit the company’s website at: http://www.zomedica.com/

To view IBN’s virtual coverage of Noble’s 20th annual small and micro-cap investor conference, visit https://ibn.fm/NobleCon20

About IBN’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating at this year’s NobleCon. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com